Endometrial Cancer Enters Immunotherapy Age – OncLive
OncLive |
Endometrial Cancer Enters Immunotherapy Age
OncLive The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors has helped propel endometrial cancer into the immunotherapy … |
